Abstract
Introduction Most people living with HIV (PLHIV) who are established on treatment in Zambia receive multi-month prescribing and dispensing (MMSD) of antiretroviral therapy (ART) and are enrolled in less-intensive differentiated service delivery (DSD) models, such as Fast Track (FT), in which clients pick up ART every 3-6 months and make clinical visits to health facilities every 6 months. In 2019, Zambia introduced Isoniazid Preventive Therapy (IPT) with scheduled visits at 2 weeks and 1, 3, and 6 months. The asynchronous IPT and HIV appointment schedules were inconvenient and not client centered. In response, we piloted integrated MMSD/IPT in the FT HIV treatment model.
Methods We implemented and evaluated a proof-of-concept pilot project at one purposively selected high-volume facility in Lusaka, Zambia between July 2019 and May 2020. We sensitized stakeholders, adapted training materials and standard operating procedures, and screened adults in FT for TB as per national guidelines. Participants received structured TB/IPT education, a 6-month supply of isoniazid and ART, an aligned 6th month IPT/MMSD clinic appointment, and phone appointments at 2 weeks and months 1-5 following IPT initiation. We used descriptive statistics to characterize IPT completion rates, phone appointment keeping, side effect frequency and Fisher’s exact test to determine if these varied by participant characteristics. Notes from monthly meetings and discussions were used to synthesize key lessons learned.
Results 1,167 clients were screened for eligibility and 818 (70.1%) were enrolled. Two thirds (66%) were female, median age was 42 years, and 56.6% had been on ART for ≥ 5 years. 738 (90.2%) completed a 6-month course of IPT and 66 (8.1%) reported IPT-related side effects. 539 clients (65.9%) attended all 7 telephone appointments. There were no significant differences in these outcomes by age, sex, or time on ART. Lessons learnt include the value of promoting project ownership, client empowerment, securing supply chain, adapting existing processes, and cultivating a collaborative structured learning environment.
Conclusions Integrating multi-month dispensing and telephone follow up of IPT into the FT HIV treatment model is a promising approach to scaling-up TB preventive treatment among PLHIV, although limited by barriers to consistent phone access.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part, by the Bill & Melinda Gates Foundation [grant number OPP1152764]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Consideration The University of Zambia Biomedical Research Ethics Committee (UNZABREC) approved, and the National Health Research Authority (NHRA) gave authority to conduct the pilot. Since this evaluation was implemented within routine ART program, signed informed consent was not a requirement for participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
E-mail addresses of authors:
MMM: Mpande.Mwenechanya{at}cidrz.org
MM: Muhau.Mubiana{at}cidrz.org
PS: Paul.Somwe{at}cidrz.org
KZ: khozyazyambo{at}gmail.com
MS:maureen_simwenda{at}jsh-z.com
NZ: nancyzyongwe{at}gmail.com
EK: Estella.Kalumkumya{at}cidrz.org
LKM: lkmwango{at}cihebzambia.org
MR: mr84{at}cumc.columbia.edu
FM: fmpasela{at}clintonhealthaccess.org
FC: fred.chungu{at}gmail.com
FM: felimwa{at}yahoo.com
PP:pp2332{at}cumc.columbia.edu
CMB: Carolyn.Bolton{at}cidrz.org
SB: Samuel.Bosomprah{at}cidrz.org
AS: Anjali.Sharma{at}cidrz.org
KM: mortonkhunga{at}yahoo.com
PK: pk2587{at}cumc.columbia.edu
LBM: lbmulenga{at}yahoo.com
PL: lungupatrick99{at}gmail.com
PLM: priscillalloyd2{at}icloud.com
Data Availability
The Government of Zambia allows data sharing when applicable local conditions are satisfied. In this case, the data from the study will be made available to any interested researchers upon request. The CIDRZ Ethics and Compliance Committee is responsible for approving such request. To request data access, one must write to the Committee chair/Chief Scientific Officer, Dr. Roma Chilengi, (Roma.Chilengi{at}cidrz.org) or the Secretary to the Committee/Head of Research Operations, Ms. Hope Mwanyungwi (Hope.Mwanyungwi{at}cidrz.org) mentioning the intended use for the data. The Committee will then facilitate review and authorization to release the data as requested. Data requests must include contact information, a research project title, and a description of the intended use.